Theravance Biopharma (TBPH) Competitors $9.59 -0.14 (-1.44%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TBPH vs. BLTE, HRMY, GPCR, GLPG, XNCR, MNKD, DVAX, INDV, EVO, and SDGRShould you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Belite Bio (BLTE), Harmony Biosciences (HRMY), Structure Therapeutics (GPCR), Galapagos (GLPG), Xencor (XNCR), MannKind (MNKD), Dynavax Technologies (DVAX), Indivior (INDV), Evotec (EVO), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry. Theravance Biopharma vs. Belite Bio Harmony Biosciences Structure Therapeutics Galapagos Xencor MannKind Dynavax Technologies Indivior Evotec Schrödinger Belite Bio (NASDAQ:BLTE) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership. Is BLTE or TBPH more profitable? Belite Bio has a net margin of 0.00% compared to Theravance Biopharma's net margin of -78.18%. Theravance Biopharma's return on equity of -24.79% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -31.94% -30.73% Theravance Biopharma -78.18%-24.79%-13.43% Do analysts recommend BLTE or TBPH? Belite Bio presently has a consensus target price of $89.00, indicating a potential upside of 38.80%. Theravance Biopharma has a consensus target price of $13.75, indicating a potential upside of 43.38%. Given Theravance Biopharma's higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Theravance Biopharma 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has better valuation & earnings, BLTE or TBPH? Belite Bio has higher earnings, but lower revenue than Theravance Biopharma. Belite Bio is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$31.63M-$1.11-57.77Theravance Biopharma$63.19M7.46-$55.19M-$1.01-9.50 Does the MarketBeat Community believe in BLTE or TBPH? Theravance Biopharma received 311 more outperform votes than Belite Bio when rated by MarketBeat users. However, 96.77% of users gave Belite Bio an outperform vote while only 62.80% of users gave Theravance Biopharma an outperform vote. CompanyUnderperformOutperformBelite BioOutperform Votes3096.77% Underperform Votes13.23%Theravance BiopharmaOutperform Votes34162.80% Underperform Votes20237.20% Do institutionals and insiders believe in BLTE or TBPH? 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 6.9% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, BLTE or TBPH? Belite Bio has a beta of -1.64, suggesting that its stock price is 264% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Does the media prefer BLTE or TBPH? In the previous week, Theravance Biopharma had 2 more articles in the media than Belite Bio. MarketBeat recorded 2 mentions for Theravance Biopharma and 0 mentions for Belite Bio. Theravance Biopharma's average media sentiment score of 0.56 beat Belite Bio's score of -0.55 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Belite Bio Negative Theravance Biopharma Positive SummaryTheravance Biopharma beats Belite Bio on 11 of the 17 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TBPH vs. The Competition Export to ExcelMetricTheravance BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$471.58M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-9.5010.5991.3417.19Price / Sales7.46195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book2.245.104.794.78Net Income-$55.19M$151.51M$120.07M$225.60M7 Day Performance-2.94%-2.15%-1.89%-1.24%1 Month Performance-0.21%-3.14%11.45%3.36%1 Year Performance-15.36%11.50%30.61%16.58% Theravance Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TBPHTheravance Biopharma2.1649 of 5 stars$9.59-1.4%$13.75+43.4%-12.6%$471.58M$63.19M-9.50359BLTEBelite Bio2.1044 of 5 stars$62.71+0.6%$89.00+41.9%+44.1%$1.92BN/A-56.1620HRMYHarmony Biosciences4.7827 of 5 stars$32.72+1.0%$47.00+43.6%+7.0%$1.87B$681.88M15.35200Analyst ForecastAnalyst RevisionGPCRStructure Therapeutics2.3736 of 5 stars$31.41+0.5%$85.67+172.7%-15.4%$1.80BN/A-42.23136Analyst ForecastNews CoverageGap UpGLPGGalapagos0.6163 of 5 stars$27.00+0.7%$30.75+13.9%-31.4%$1.78B$260.09M0.001,123XNCRXencor4.3204 of 5 stars$25.02+4.1%$36.56+46.1%+18.4%$1.75B$168.34M-7.51280MNKDMannKind3.195 of 5 stars$6.25-4.4%$8.67+38.7%+105.4%$1.72B$198.96M93.43400Analyst UpgradeAnalyst RevisionNews CoverageDVAXDynavax Technologies4.6668 of 5 stars$12.96flat$22.00+69.8%-4.1%$1.70B$260.81M100.00408News CoveragePositive NewsINDVIndivior2.456 of 5 stars$12.02+3.9%$16.00+33.1%-22.3%$1.66B$1.18B-294.251,164Positive NewsEVOEvotec2.387 of 5 stars$4.67+4.0%$5.93+27.1%-60.5%$1.65B$777.05M0.005,061Positive NewsSDGRSchrödinger2.3678 of 5 stars$21.59+3.6%$32.90+52.4%-42.3%$1.57B$216.67M-8.90867Positive News Related Companies and Tools Related Companies BLTE Alternatives HRMY Alternatives GPCR Alternatives GLPG Alternatives XNCR Alternatives MNKD Alternatives DVAX Alternatives INDV Alternatives EVO Alternatives SDGR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TBPH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
